GENE ONLINE|News &
Opinion
Blog

China Approves Avastin’s New Indication

by GeneOnline
Share To

As the world’s first anti-tumor angiogenesis treatment drug, Avastin was approved in China to treat colorectal cancer and non-small cell lung cancer ( NSCLC ) indications. On September 21, Roche announced that Avastin had been approved by the National Medical Products Administration (NMPA) of China to treat adult patients with recurrent glioblastoma (GBM).

Avastin is a humanized monoclonal antibody lgG1 developed by Roche. Avastin can bind to tumor Vascular Endothelial Growth Factor (VEGF) to not stimulate the growth of blood vessels. The blood, oxygen, and other nutrients required for tumor growth are blocked, preventing their growth or spreading to other parts of the body, and ultimately achieving anti-cancer effects.

Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults. In the West, the annual incidence or number of new diagnoses is 2 to 3 per 100,000 people. GBM accounts for 12% to 15% of all intracranial tumors and 50% to 60% of astrocytoma. GBM can invade and infiltrate the normal surrounding brain tissue extensively, making complete resection impossible. Even with comprehensive treatments such as surgery, radiotherapy and chemotherapy, GBM patients are still very prone to relapse and die of tumors quickly. GBM is considered being one of the most challenging tumors in neurosurgery.

This new indication’s approval is mainly based on a multi-center, open-label, randomized controlled, pivotal phase III clinical trial EORTC 26101. This study confirmed that compared with chemotherapy alone, Avastin-based treatment prolonged the time to progression-free survival or the time to death (median PFS: 4.2 months vs. 1.5 months, HR=0.52, 95%CI: 0.41-0.64), the risk of disease progression can be reduced by 51%. During the progression-free survival period, patients in remission showed more stable global health scores and cognitive functions than non-remission patients. This means that Avastin will bring new treatment options for Chinese GBM patients. The approval of Avastin this time fills up the gap in GBM treatment in China. It is of great significance to improving the level of GBM diagnosis and treatment in China and will bring good news to patients who lack effective treatment options.


Partner Article, By James Hou, Ph.D.

 

 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Roche’s Polivy Wins Support From FDA Adcom For Treating B-Cell Cancer
2023-03-10
Roche Returns Gavreto Rights To Blueprint After Ditching Collaboration
2023-02-24
Biocon and Viatris Hit Another FDA Wall with Avastin Biosimilar
2023-02-13
LATEST
GSK Bets $593 Million To License Scynexis’ Oral Antifungal
2023-03-31
3D Printed Brain Model Could Aid in Neurosurgery
2023-03-31
Latest Study on Neuronal Gene Expression May Shed Light on the Memory Formation Process
2023-03-30
Emergent BioSolutions’ Over-The-Counter Naloxone Nasal Spray Receives FDA Greenlight
2023-03-30
Current Trends of iPSC Manufacturing and Clinical Applications – An Interview with Professor Xianmin Zeng
2023-03-29
U.S.-German Joint Discovery May Spark Breakthrough in Diabetes Research
2023-03-29
Merck Regains Worldwide Rights to BAVENCIO After Parting Ways with Pfizer
2023-03-29
Scroll to Top